(1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine
Glioma, Mixed
Nuvation Bio Inc.Small moleculePhase 1Dormant
D
25/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 10/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Glioma, Mixed cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib National Cancer Institute (NCI) | Phase 2 | BBB |
Temsirolimus Andrew B Lassman, MD | Phase 1/2 | B |
Perifosine Andrew B Lassman, MD | Phase 1/2 | B |
Veliparib National Cancer Institute (NCI) | Phase 1/2 | B |
Streptozocin Emory University | Phase 2 | B |
View all 39 →
Same molecule, other indications
(1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →